MU1140-S

MU1140-S is an engineered analog of the lantibiotic mutacin 1140, a ribosomally synthesized and post-translationally modified peptide (RiPP) originally produced by Streptococcus mutans and classified within the epidermin-type A(I) lantibiotics. Native MU1140 exerts potent activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and other multidrug-resistant pathogens, by binding the cell-wall precursor lipid II to block peptidoglycan synthesis and by disrupting bacterial membranes, leading to rapid bactericidal effects against many Gram-positive species.[1][3][5] MU1140-S represents a stability- and pharmacokinetic-optimized variant designed to improve proteolytic stability and systemic exposure relative to native MU1140, with the goal of systemic and local treatment of serious Gram-positive infections such as MRSA bacteremia, skin and soft-tissue infections, and Clostridioides difficile–associated diarrhea, building on the broader program of mutacin 1140 variant design and selection.[2][5][8][11][13]